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MicroRNAs (miRNAs) in body fluids have received attention as potential biomarkers 
of organ damage because miRNAs that are highly or specifically expressed in a given organ 
are likely released into body fluids as a result of damage to that organ. We previously 
determined that the plasma miRNA profile in rats was dramatically changed due to 
acetaminophen (APAP)-induced pericentral necrosis and methapyrilene (MP)-induced 
periportal necrosis in the liver. The purpose of this study was to examine whether the 
expression of hepatic miRNAs is differentially modulated at different zones due to injury and 
to examine the relationship of the hepatic miRNA profile with the changes in the plasma 
miRNA expression profile. Through the laser microdissection of the periportal and periportal 
regions of the liver and TaqMan microRNA Array analysis, we found that 49 miRNAs are 
differentially expressed between the pericentral and periportal regions of control rats. In both 
APAP- and MP-treated rats, the miRNAs that presented decreased expression dominated in 
both the injured and non-injured areas compared with the miRNAs that exhibited increased 
expression. The changes in miRNA expression in each region of the liver were compared with 
those observed in the plasma. Of the 301 plasma miRNAs with expression that was changed 
as a result of APAP administration, only 21% were changed in the injured area of the liver. Of 
the 263 plasma miRNAs with expression that was changed due to MP administration, only 
24% were changed in the injured area of the liver. Thus, the miRNA expression profiles in the 
plasma do not merely reflect the release of miRNAs from the damaged cells in the liver. This 
report provides the first demonstration of zonal miRNA expression in the liver and of the 
relationship of the miRNA expression profile in a tissue with the plasma miRNA profile. 
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     miRNAs are small non-coding RNAs that control gene expression through translational 
repression or mRNA degradation. miRNAs regulate various biological processes, such as 
lipid metabolism (Esau et al., 2006), apoptosis (Cimmino et al., 2005), and carcinogenesis (Lu 
et al., 2005). To date, more than 2500, 1900, and 700 miRNAs have been identified in human, 
mouse, and rat, respectively. miRNA expression varies from highly specific to ubiquitous. It 
has been demonstrated that the aberrant expression of miRNAs is associated with a variety of 
diseases, including cancer (Dillhoff et al., 2009), viral hepatitis (Ura et al., 2009), and heart 
disease (Ikeda et al., 2007). In 2008, it was reported that miRNAs stably exist in plasma 
(Chim et al., 2008, Mitchell et al., 2008) and serum (Lawrie et al., 2008, Mitchell et al., 2008). 
Subsequent studies reported the presence of miRNAs in various body fluids, including saliva 
(Park et al., 2009), urine (Hanke et al., 2010), breast milk (Kosaka et al., 2010), and tears 
(Weber et al., 2010). The miRNAs in body fluids, which may reflect the changes in the 
miRNA expression levels in tissues, have received considerable attention as biomarkers of 
disease (Cortez and Calin, 2009).  
     We previously investigated the plasma miRNA profile in rats with acute liver injury as 
a result of a single administration of APAP or MP (Yamaura et al., 2012) and demonstrated 
that approximately 300 plasma miRNAs are altered due to APAP- or MP-induced liver injury. 
Most of the altered miRNAs (> 85%) were common to the two models, and the remaining 
miRNAs were specifically changed in one of the models. APAP and MP induce hepatocellular 
injury at the pericentral and periportal regions, respectively. It would be reasonable to 
speculate that the specifically altered miRNAs in the plasma may reflect the change in the 
miRNA expression profile at the pericentral and periportal regions that exhibit hepatocellular 
necrosis. Although a previous study using a mouse model with liver injury caused by the 
administration of APAP reported that the miRNAs that exhibited an increased expression level 
in the plasma were decreased in the liver (Wang et al., 2009), the relationship of the changes 




































































present study, we examined the miRNA expression profiles at the pericentral and periportal 
regions of the liver in two rat models of liver injury to clarify whether the miRNAs in the 
liver are uniformly or variably expressed through the region and to understand the 
relationship between the plasma and tissue miRNA expression profiles. 
 
1. Materials and methods 
1.1. Chemicals and reagents 
    APAP and MP were purchased from Wako Pure Chemicals (Osaka, Japan) and 
Sigma-Aldrich (St. Louis, MO), respectively. The RNAqueous Kit, mirVana PARIS Kit, 
RNAqueous Kit, Megaplex Pools, TaqMan MicroRNA Reverse Transcription Kit, TaqMan 
MicroRNA Assays, TaqMan 2x Universal PCR Master Mix (No AmpErase UNG), and 
TaqMan Rodent MicroRNA Array v2.0 were obtained from Applied Biosystems (Foster City, 
CA). All of the other chemicals and solvents were of the highest grade commercially 
available. 
 
1.2. Animal models 
    The animal maintenance and treatments were conducted in accordance with the National 
Institutes of Health Guide for Animal Welfare of Japan and were approved by the Institutional 
Animal Care and Use Committee of Kanazawa University, Japan. The study was approved by 
the Animal Ethics Committee of Kanazawa University (No. 31203). Male five-week-old 
Sprague-Dawley rats were purchased from Japan SLC (Hamamatsu, Japan). The rats were 
housed in a controlled environment (temperature 25 ± 1°C, humidity 50 ± 10%, and 12-h 
light/12-h dark cycle) in the institutional animal facility with access to food and water ad 
libitum. Each set of six rats was orally administered 1,000 mg/kg APAP suspended in 0.5% 
carboxymethylcellulose (CMC) after fasting for 48 h, 300 mg/kg MP dissolved in 0.5% CMC, 
or vehicle. Twenty-four hours after administration, their blood and liver were collected. Using 
EDTA as an anticoagulant, the plasma was separated by centrifugation and maintained at 




































































remaining part was stored at -80°C. 
 
1.3. Biochemical assay and pathological examination 
    The plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total 
bilirubin (T-Bil) levels were determined using Dri-Chem 4000 (FUJIFILM Saitama, Japan) 
according to the manufacturer’s instructions. The formalin-fixed samples were embedded in 
paraffin, sectioned, and then stained with hematoxylin and eosin (Wako Pure Chemicals, 
Osaka, Japan) for microscopic examination.  
 
1.4. Laser microdissection and RNA isolation 
    Part of the frozen livers were embedded in O.C.T. compound (Sakura Finetek Japan, 
Tokyo, Japan), cut into 20-m-thick sections, and stained with 10% hematoxylin and eosin. 
The pericentral and periportal regions of the livers from rats administered APAP, MP, or 
vehicle were collected by laser microdissection using an Application Solutions Laser 
Microdissection System (Leica Microsystems, Wetzler, Germany). The total RNA from the 
microdissected sections was extracted using the RNAqueous Kit according to the 
manufacturer’s protocol, and the total RNA from the same group was pooled. 
 
1.5. TaqMan microRNA array analysis 
    The cDNAs were synthesized from the pooled total RNA using Megaplex Pools 
according to the manufacturer’s protocol. Preamplification was performed by the addition of 
2x TaqMan PreAmp Master Mix and 10x Megaplex PreAmp Primers to the cDNA sample. 
TaqMan 2x Universal PCR Master Mix (No AmpErase UNG) was then added to the 
preamplification products. The mixture was applied to individual ports of TaqMan Array 
Rodent MicroRNA A+B Cards Sets v2.0 384-well microfluidics cards containing 375 (A 
array) or 210 (B array) primer-probe sets for individual miRNAs. Quantitative real-time PCR 
was performed using a 7900HT Fast Real-Time PCR system (Applied Biosystems) with the 




































































threshold (Ct) method. The Ct values ranged from 0 to 40. The miRNAs that gave Ct values 
greater than 32 in all of the groups were omitted from the data analysis because this 32 is the 
cut-off value recommended by the manufacturer. The data are presented as (40 - Ct). The ΔCt 
values [ΔCt = (40 - Ct control) - (40 - Ct model)] were calculated as fold changes. The 
miRNAs showing expression changes of at least two-fold were analyzed. A heat map was 
generated with Microsoft Excel 2010. 
 
1.6. Statistical analysis 
    The data are expressed as the means ± SD. The comparisons of two groups were made 
using Mann-Whitney’s U-test. A value of P < 0.05 was considered statistically significant. 
 
2. Results 
2.1. ALT, AST, and histopathology of the liver  
    After the administration of APAP and MP, the plasma ALT and AST levels were 
significantly elevated (Fig. 1A). The histopathological analysis revealed that APAP caused 
hepatocellular necrosis at the pericentral regions, whereas MP caused hepatocellular necrosis 
at the periportal region (Fig. 1B). These two models were used for the subsequent studies. 
 
2.2. miRNA expression at the pericentral and periportal regions of the liver 
    The miRNA expression at pericentral and periportal regions of the liver was determined 
by TaqMan microRNA array analysis. The numbers of the detected miRNAs and the miRNAs 
whose expression exceeded the cutoff (Ct < 32) are shown in Table 1. No large difference was 
observed in these numbers between the pericentral and periportal regions within a group or 
between the treated and control groups. Among the miRNAs with Ct values less than 32 in all 
of the groups, 125 miRNAs were common to all of the groups; therefore, these 125 miRNAs 
were used for the subsequent analyses. Fig. 2 shows the heat maps of the expression of the 
125 miRNAs in each sample; note that the miRNAs are ordered based on descending 




































































exhibited high expression in both the pericentral and periportal regions in all of the samples 
are miR-709, miR-122, and miR-720. The comparison of the miRNA levels between the 
control rats and fasted-control rats revealed that 36 miRNAs presented higher levels and eight 
miRNAs exhibited lower levels at the pericentral region of the fasted-control rats (Tables 1 
and 2). At the periportal region, 52 miRNAs and two miRNAs presented higher and lower 
levels, respectively, in the fasted-control rats compared with the control rats. Among these 
miRNAs, 17 miRNAs, which are shown in bold, were found in both the pericentral and 
periportal regions. Thus, the results demonstrate that fasting affects the expression of some 
miRNAs in the liver. The comparison of the miRNA levels between the pericentral and 
periportal regions in control rats showed that 27 miRNAs exhibited higher expression levels 
in the pericentral region and that 22 miRNAs presented higher expression levels in the 
periportal region compared with the other region (Tables 1 and 3). This study provides the 
first demonstration that some miRNAs are differentially expressed at the periportal and 
periportal regions.  
After the administration of APAP, the levels of 18 miRNAs were increased and the 
levels of 27 miRNAs were decreased at the pericentral region (Table 1). At the periportal 
region, seven miRNAs and 21 miRNAs were increased and decreased, respectively. As a 
result of the administration of MP, 10 miRNAs presented increased expression and 62 
miRNAs exhibited decreased expression at the pericentral region. At the periportal region, 
four miRNAs and 56 miRNAs were increased and decreased, respectively. Thus, although the 
miRNAs that exhibited decreased expression levels were dominant, particularly in the 
MP-treated rats, there were certainly a number of miRNAs that presented increased 
expression. These miRNAs were further classified based on the fluctuation in their expression 
at another hepatic region (Table 4). Table 4 includes the numbers of the unchanged miRNAs 
as well as the altered 125 miRNAs. Of the 18 and 27 miRNAs that exhibited increased and 
decreased expression at the pericentral region in APAP-treated rats, respectively, 14 (78%) 
and 20 (74%) miRNAs were not changed at the periportal region, respectively. Thus, most of 




































































were not affected at the periportal region. It is interesting that four (57%) and 13 (62%) 
miRNAs were specifically changed at the periportal region, where hepatocytes were not 
injured. In MP-treated rats, of the four and 56 miRNAs that exhibited increased and decreased 
expression at the periportal region, respectively, three miRNAs (75%) and 42 miRNAs (75%) 
also presented changed expression levels at the pericentral region. Thus, the results 
demonstrate that a large number of miRNAs were decreased at both the periportal and 
pericentral regions. 
 
2.3. Comparison of the miRNA expression changes in the liver and plasma 
    We then sought to examine the relationship between the miRNA expression changes in the 
liver and those in the plasma because we previously reported the plasma miRNA profiles in 
these model rats (Yamaura et al., 2012). The miRNAs that were classified into nine groups 
(groups A to I) in Table 4 are specified in Table 5. In the groups that include more than 10 
miRNAs, the ten most abundant miRNAs are shown. The changes in the levels of these 
miRNAs in the plasma are shown with arrows in Table 5. Interestingly, in the APAP-treated rats, 
122 of the 125 miRNAs were increased in the plasma, regardless of the changes observed in the 
liver. The remaining three miRNAs were not changed in the plasma. In the MP-treated rats, 117 
of 125 miRNAs were increased in the plasma, six miRNAs were unchanged, and two miRNAs 
were decreased in the plasma. The fold changes of these miRNAs in the liver (pericentral and 
periportal regions) and plasma are shown in Figs. 3 and 4. In the groups with more than five 
miRNAs, the five most abundant miRNAs are shown. Reciprocal changes in the miRNAs 
between the liver and plasma (decrease in the liver and increase in plasma) were observed in 
some cases, but this relationship was not general. Of special interest is that the miRNAs that 
were not affected in the liver at all were markedly increased in the plasma, as shown in group E. 
Thus, the relationship between the changes in the miRNA levels in the plasma and tissue is not 
simple. 
     We then examined the expression changes in the liver of the miRNAs that were 




































































increased and that six and 10 miRNAs are decreased in the rat plasma as a result of APAP- 
and MP-induced liver injury, respectively (Yamaura et al., 2012). In our previous study, 
several miRNAs for which two probes were included on the array were counted individually. 
Excluding the overlapped miRNAs, the numbers of plasma miRNAs that were changed by 
APAP and MP administration were recalculated to 301 and 263 miRNAs, respectively. 
Among the 301 miRNAs that exhibited a change in their expression level in the APAP-treated 
rats, 48 miRNAs (16%) were changed only at the pericentral region, 14 miRNAs (5%) were 
changed at both the pericentral and periportal regions, and 27 miRNAs (9%) were changed 
only at the periportal region. Among the 263 miRNAs that presented a changed expression 
level in the MP-treated rats, 32 miRNAs (12%) were changed only in the pericentral region, 
44 miRNAs (17%) were changed at both the pericentral and periportal region, and 18 
miRNAs (7%) were changed only at the periportal region. Collectively, most (~70%) of the 
miRNAs whose levels were changed in the plasma of rats with liver injury were not changed 
in the liver.  
 
3. Discussion  
    In this study, we examined the hepatic miRNA expression in rats with liver injury to 
evaluate the relationship between the changes in the plasma miRNA profile and to determine 
whether the miRNA expression is differently modulated at injured and not-injured regions. 
We also examined whether miRNA expression varies between different zones in the normal 
liver and whether hepatic miRNA expression is affected by fasting. 
    In the rat liver, we found that the three most abundant miRNAs are miR-709, miR-122, 
and miR-720. The high expression of miR-709 and miR-720 was unexpected because it is 
known that miR-122 constitutes 70% of the total hepatic miRNAs (Lagos-Quintana et al., 
2002, Chang et al., 2004). We noticed that miR-720 had been removed from the database 
(http://www.mirbase.org/index.shtml) because Schopman et al. (2010) reported that the 
sequence annotated as miR-720 is likely to be a fragment of a tRNA. Although miR-709 




































































that of a tRNA, indicating that it may also be misdetection. Supporting this assumption, the 
abundant miRNAs in the rat liver (other than miR-709 and miR-720), such as miR-122, 
miR-126-3p, miR-191, and miR-146a, were also found to be highly expressed in human 
hepatocytes in our previous study (Takahashi et al., 2014). 
     We found that fasting changes the expression of some miRNAs in the rat liver. 
Although we did not examine the causes of the changes in this study, the changes in 
glycolysis, glucogenesis, ketone body metabolism, fatty acid metabolism, and lipid metabolic 
processes due to fasting would be possible causes. It would be of interest to investigate 
whether the expression of the target genes of these miRNAs is modulated because it has been 
reported that fasting changes the expression of various genes in the liver (Zhang et al., 2011); 
in other words, it would be interesting to determine whether the changes in gene expression 
are due to direct effects of fasting or indirect effects due to changes in the miRNA expression 
profile. 
     We found that 27 and 22 miRNAs of the 125 miRNAs were dominantly expressed at 
the pericentral and periportal regions, respectively, in the normal rat liver. This finding is not 
surprising because it is well known that some genes or proteins show zonal expression. For 
example, drug-metabolizing enzymes are predominantly expressed at the pericentral region 
(Hailfinger et al., 2006), whereas cadherin and ATP-citrate lyase are predominantly expressed 
at the periportal region (Braeuning et al., 2006). It has been reported that such zonal 
expressions are due to differences in transcriptional regulation (Gebhardt, 1992, Jungermann, 
1995). Because the expression of miRNAs is regulated at the transcriptional level to a greater 
or lesser extent, the zonal expression of miRNAs may be due to differences in their 
transcriptional regulation. Additionally, differences in post-transcriptional regulation, i.e., 
maturation step or degradation, may also contribute to the zonal expression. It would also be 
of interest to investigate whether such differences in miRNA expression between regions may 
cause differences in the expression of the target mRNAs between regions.  
     We evaluated the changes in miRNA expression in the liver caused by the 




































































periportal regions, respectively. In APAP-treated rats, 45 and 30 miRNAs were changed at the 
pericentral or periportal regions, respectively, and in the MP-treated rats, 72 and 60 miRNAs 
were changed at the pericentral or periportal regions, respectively. It was interesting that 
miRNA expression was affected at the region where hepatocytes were not injured. Because 
we previously reported that 301 and 263 miRNAs were changed in the plasma of APAP- and 
MP-treated rats, respectively (Yamaura et al., 2012), this study demonstrated that the number 
of miRNAs changed in the liver is lower than that of miRNAs change in the plasma. In both 
groups, miRNAs that exhibit decreased expression were dominant in the liver compared with 
the miRNAs that presented increased expression. This finding is reminiscent of the fact that, 
in the plasma of rats with liver injury, the miRNAs that presented increased expression were 
dominant compared with the miRNAs that exhibited decreased expression (Yamaura et al., 
2012), implying reciprocal changes in miRNAs between the liver and plasma. It is generally 
believed that miRNAs that are highly expressed in a tissue would be plasma biomarkers of 
tissue injury. However, an inverse association was observed for some miRNAs, but there were 
many exceptions (Table 5 and Fig. 5). For example, miR-155 was increased at the pericentral 
region and in the plasma in APAP-treated rats. miR-155 has been reported to be expressed in 
immune cells, including B cells (Rodriguez et al., 2007; Thai et al., 2007), T cells (Haasch et 
al., 2002), and macrophages (O’Connell et al., 2007; Taganov et al., 2006), and to be 
upregulated as a result of activation by immune stimuli, such as inflammatory cytokines. Thus, 
the increased level of miR-155 in the liver may be due to the activation of immune cells, and 
this may be reflected in the increased level of this miRNA observed in the plasma. As shown 
in Fig. 5, many of the changed miRNAs in the plasma, including miR-150 and miR-223, were 
not altered in the liver. Recently, Pritchard et al. (2012) reported that the circulating miRNAs 
are largely obtained from blood cells. It appears that miR-150 is the most abundant miRNA in 
lymphocytes, and miR-223 is the most abundant miRNA in platelets, neutrophils, eosinophils, 
and monocytes. Accordingly, the changes in the expression levels of these miRNAs in the 




































































    In summary, the present study clarified that 1) certain miRNAs in the liver are 
differentially expressed between the pericentral and periportal regions, 2) fasting affects the 
expression of a set of miRNAs in the liver, 3) the miRNA expression in the liver is modulated 
not only in the injured region but also the non-injured region, and 4) a reciprocal relationship 
between the miRNAs that presented increased levels in the plasma and the miRNAs that 
exhibit decreased levels in the liver is not necessarily found.  
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Fig. 1. Plasma ALT and AST levels and histopathological presentation of liver injury in rat 
models. (A) Plasma ALT and AST levels in rats after the administration of APAP or MP. (B) 
Histopathological changes in rats after the administration of APAP or MP. The data are the 
means ± SD (n = 4 to 8). **Significantly different from the control group (P < 0.01). The liver 
sections were stained with HE. Original magnification, ×200. CV: central vein, P: portal 
region. 
 
Fig. 2. Heat map of the expression profiles of miRNAs in the pericentral and periportal 
regions of the liver from APAP- and MP-treated rats. The miRNAs were seriated in 
descending order of the expression level in the control rats. 
 
Fig. 3. Fold change of the miRNAs whose expressions were upregulated at the CV and P (A), 
upregulated only at the CV (B), upregulated at the pericentral region and downregulated at the 
P (C), upregulated only at the P (D), not changed (E), downregulated only at the P (F), 
downregulated at the CV and upregulated at the P (G), downregulated only at the CV (H), and 
downregulated at the CV and P (I) in APAP-administered rats.  
 
Fig. 4. Fold change of the miRNAs whose expressions were upregulated at the CV and P (A), 
upregulated only at the CV (B), upregulated at the pericentral region and downregulated at the 
P (C), upregulated only at the P (D), not changed (E), downregulated only at the P (F), 
downregulated at the CV and upregulated at the P (G), downregulated only at the CV (H), and 
downregulated at the CV and P (I) in MP-administered rats. 
 
Fig. 5. Composition of miRNAs whose expression was changed as a result of hepatocellular 




















































Table 1. The numbers of miRNAs whose expression was detected or changed (by at least two-fold) in the pericentral and periportal regions of the 












Ctrl: control, CV: central vein, P: portal vein, Treated: APAP or MP, -: not determined.  
* Fasted ctrl or Ctrl.
Treatment Region Detected Ct < 32 Fasted ctrl > Ctrl  Fasted ctrl < Ctrl CV > P CV < P Treated > Ctrl*  Treated < Ctrl* 
Fasted ctrl 
CV 284 183 36 8 - -   
P 308 188 52 2 - -   
APAP  
CV 315 187 - - - - 18 27 
P 311 187 - - - - 7 21 
Ctrl 
CV 263 176   27 22   
P 279 165       
MP 
CV 239 144 - - - - 10 62 




































































Table 2. Effects of fasting on miRNA expression in the pericentral and periportal regions of the liver. 
The miRNAs shown in bold are common to the pericentral and periportal regions. 
  Pericentral region     Periportal region 
miRNAs 
Fasted-ctrl 
(40 - Ct) 
Ctrl 
(40 - Ct) 
Fold   miRNAs 
Fasted-ctrl 
(40 - Ct) 
Ctrl 
(40 - Ct) 
Fold 
Fasted-ctrl > Ctrl (36 miRNAs)    Fasted-ctrl > Ctrl (52 miRNAs)   
mmu-miR-222 15.2 21.6 84.4  mmu-miR-99a 12.2 16.2 16.0 
mmu-miR-706 8.6 13.2 24.3  mmu-miR-100 13.0 16.2 8.6 
mmu-miR-690 14.8 19.0 18.4  mmu-miR-467a* 12.5 15.4 8.0 
mmu-miR-135a* 10.4 14.5 16.0  mmu-miR-706 9.6 12.4 7.0 
mmu-miR-877* 8.6 12.0 10.6  mmu-miR-130a 9.6 12.2 6.1 
mmu-miR-101b 12.9 16.3 10.6  mmu-let-7i 11.3 13.9 6.1 
mmu-miR-193* 11.5 14.4 8.0  mmu-let-7b 14.4 16.8 5.3 
mmu-miR-22 11.1 14.0 7.5  mmu-miR-99b 10.4 12.8 5.3 
mmu-miR-467a* 12.3 15.2 7.5  mmu-miR-135a* 11.7 14.0 4.9 
mmu-miR-93* 9.7 12.5 7.0  mmu-let-7c 15.6 17.9 4.9 
rno-miR-664 13.6 16.4 6.5  mmu-miR-125b-5p 13.2 15.3 4.6 
rno-miR-28* 8.6 11.3 6.5  mmu-miR-690 15.2 17.4 4.3 
mmu-miR-21* 8.9 11.6 6.1  mmu-miR-328 13.6 15.6 4.3 
mmu-miR-378 13.1 15.5 5.3  mmu-miR-21 12.8 14.8 4.0 
mmu-miR-31* 11.3 13.7 5.3  mmu-miR-497 10.1 12.1 4.0 
mmu-miR-30e* 15.1 17.5 5.3  mmu-miR-467b* 8.7 10.6 3.7 
mmu-miR-30a* 15.1 17.4 4.6  mmu-miR-145 17.4 19.2 3.5 
mmu-miR-709 21.7 23.9 4.3  mmu-miR-25 10.2 12.0 3.5 
mmu-miR-674* 9.6 11.7 4.3  mmu-miR-200b 12.8 14.6 3.2 
mmu-miR-678 9.7 11.8 4.3  mmu-miR-26a 16.1 17.8 3.2 
mmu-miR-99a 13.0 15.0 4.0  mmu-miR-30a 14.3 16.0 3.2 
rno-miR-125b* 9.0 10.9 4.0  mmu-miR-27a 9.5 11.2 3.2 
mmu-miR-28* 12.4 14.3 3.7  mmu-miR-375 12.5 14.1 3.2 
mmu-miR-872* 11.2 13.1 3.5  mmu-miR-193* 11.9 13.5 3.0 
mmu-miR-720 21.2 22.9 3.2  mmu-miR-301b 9.8 11.3 3.0 
mmu-miR-455* 8.0 9.6 3.0  mmu-miR-93* 12.0 13.5 2.8 
mmu-miR-188-5p 9.5 11.0 3.0  mmu-miR-335-5p 10.1 11.6 2.8 
mmu-miR-375 13.1 14.5 2.6  mmu-miR-29c 11.4 12.9 2.8 
mmu-miR-467b* 9.0 10.4 2.6  mmu-miR-222 15.8 17.3 2.8 
mmu-miR-29a 15.2 16.5 2.5  mmu-miR-26b 13.5 15.0 2.8 
mmu-miR-125b* 9.3 10.6 2.3  mmu-miR-152 13.3 14.8 2.8 
mmu-miR-425* 8.4 9.6 2.3  mmu-miR-532-3p 11.8 13.3 2.8 
rno-miR-7a* 11.1 12.4 2.3  mmu-miR-29a 14.7 16.1 2.8 
mmu-miR-100 13.8 14.9 2.1  mmu-miR-181a 9.5 11.0 2.8 
mmu-miR-19a 13.1 14.2 2.1  mmu-miR-28 11.6 13.0 2.6 
mmu-miR-877 8.5 9.6 2.1  mmu-miR-92a 17.0 18.4 2.5 
     mmu-miR-138 13.4 14.7 2.5 
Fasted-ctrl < Ctrl (8 miRNAs)    mmu-miR-93 12.1 13.5 1.3 
mmu-miR-200a 12.8 9.8 0.1  mmu-miR-188-5p 9.2 10.5 2.5 
mmu-miR-200c 13.3 11.4 0.3  mmu-miR-877* 10.9 12.1 2.3 
mmu-miR-151-3p 11.1 9.6 0.4  mmu-let-7e 16.8 18.0 2.3 
mmu-miR-335-3p 9.8 8.3 0.4  mmu-miR-19a 12.2 13.4 2.3 
mmu-miR-155 13.9 12.5 0.4  mmu-miR-17 15.9 17.1 2.3 
mmu-miR-365 14.7 13.4 0.4  mmu-miR-678 9.8 11.0 2.3 
mmu-miR-214 13.4 12.1 0.4  mmu-miR-143 13.3 14.4 2.1 
mmu-miR-99b* 11.8 10.8 0.5  mmu-miR-378 14.3 15.4 2.1 
     mmu-miR-126-5p 14.6 15.7 2.1 
     mmu-miR-331-3p 13.1 14.2 2.1 
     mmu-miR-140 13.9 15.0 2.1 
     mmu-miR-199a-3p 12.8 13.8 2.0 
     mmu-miR-139-5p 15.2 16.2 2.0 
         
     Fasted-ctrl < Ctrl (2 miRNAs)   
     mmu-miR-322* 11.8 9.8 0.3 




































































Table 3. miRNAs whose expression was different between the pericentral and periportal regions of the liver. 
   Number of miRNAs     Number of miRNAs 
miRNAs CV P Fold   miRNAs CV P Fold 
CV > P (27 miRNAs)     CV < P (22 miRNAs)    
mmu-miR-130a 9.6 11.7 4.3  mmu-miR-322* 11.8 8.9 0.1 
mmu-miR-148a 12.2 14.3 4.3  mmu-miR-200c 15.9 13.3 0.2 
mmu-miR-335-5p 10.1 11.9 3.5  mmu-miR-877* 10.9 8.6 0.2 
mmu-miR-21 12.8 14.4 3.0  mmu-miR-31* 13.6 11.3 0.2 
mmu-miR-26b 13.5 15.1 3.0  mmu-miR-93* 12.0 9.7 0.2 
mmu-miR-532-3p 11.8 13.3 2.8  rno-miR-28* 10.8 8.6 0.2 
mmu-miR-335-3p 8.3 9.8 2.8  rno-miR-7a* 13.0 11.1 0.3 
mmu-miR-27a 9.5 10.9 2.6  rno-miR-125b* 10.8 9.0 0.3 
mmu-miR-194 14.5 15.9 2.6  mmu-miR-200a 14.3 12.8 0.3 
mmu-miR-93 12.1 13.5 2.5  mmu-miR-674* 11.1 9.6 0.4 
mmu-miR-126-5p 14.6 15.9 2.5  mmu-miR-101b 14.3 12.9 0.4 
mmu-let-7i 11.3 12.6 2.5  mmu-miR-30e* 16.5 15.1 0.4 
mmu-miR-200b 12.8 14.1 2.5  mmu-miR-184 13.2 11.9 0.4 
mmu-miR-30d 11.9 13.1 2.5  rno-miR-664 14.9 13.6 0.4 
mmu-miR-151-3p 9.9 11.1 2.3  mmu-miR-135a* 11.7 10.4 0.4 
mmu-miR-26a 16.1 17.3 2.3  mmu-miR-22 12.3 11.1 0.4 
mmu-miR-17 15.9 17.1 2.3  mmu-miR-378 14.3 13.1 0.4 
mmu-miR-122 20.5 21.7 2.3  mmu-miR-30a* 16.3 15.1 0.4 
mmu-miR-106a 15.9 17.0 2.1  mmu-miR-872* 12.4 11.2 0.4 
mmu-miR-365 13.6 14.7 2.1  mmu-miR-125b* 10.4 9.3 0.5 
mmu-let-7b 14.4 15.5 2.1  mmu-miR-28* 13.5 12.4 0.5 
mmu-miR-497 10.1 11.2 2.1  mmu-miR-720 22.2 21.2 0.5 
mmu-miR-192 17.2 18.3 2.1      
mmu-miR-92a 17.0 18.1 2.1      
mmu-miR-25 10.2 11.3 2.0      
mmu-let-7c 15.6 16.6 2.0      




































































Table 4. Numbers of miRNAs whose expression in the rat 




Up ± Down Sum 
Pericentral 
Up 2 14 2 18 
± 4 63 13 80 
Down 1 20 6 27 
Sum 7 97 21  125 
MP 
Periportal 
Up ± Down Sum 
Pericentral 
Up 2 7 1 10 
± 1 38 14 53 
Down 1 20 41 62 




































































Table 5. miRNAs whose expression in the pericentral or periportal regions was changed due to APAP- 
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